Based on the key indicators related to ReShape Lifesciences' liquidity, profitability, solvency, and operating efficiency, ReShape Lifesciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. At this time, ReShape Lifesciences' Inventory is comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 4 M in 2025, whereas Total Stockholder Equity is likely to drop slightly above 7.3 M in 2025. Key indicators impacting ReShape Lifesciences' financial strength include:
The essential information of the day-to-day investment outlook for ReShape Lifesciences includes many different criteria found on its balance sheet. An individual investor should monitor ReShape Lifesciences' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in ReShape Lifesciences.
Please note, the imprecision that can be found in ReShape Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ReShape Lifesciences. Check ReShape Lifesciences' Beneish M Score to see the likelihood of ReShape Lifesciences' management manipulating its earnings.
ReShape Lifesciences Stock Summary
ReShape Lifesciences competes with SINTX Technologies, Bone Biologics, Tivic Health, Nuwellis, and Tenon Medical. ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Reshape Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 47 people.
ReShape Lifesciences Key Income Statement Accounts
The reason investors look at the income statement is to determine what ReShape Lifesciences' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining ReShape Lifesciences's current stock value. Our valuation model uses many indicators to compare ReShape Lifesciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ReShape Lifesciences competition to find correlations between indicators driving ReShape Lifesciences's intrinsic value. More Info.
ReShape Lifesciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, ReShape Lifesciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ReShape Lifesciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
ReShape Lifesciences Systematic Risk
ReShape Lifesciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ReShape Lifesciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on ReShape Lifesciences correlated with the market. If Beta is less than 0 ReShape Lifesciences generally moves in the opposite direction as compared to the market. If ReShape Lifesciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ReShape Lifesciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ReShape Lifesciences is generally in the same direction as the market. If Beta > 1 ReShape Lifesciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in ReShape Lifesciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ReShape Lifesciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ReShape Lifesciences growth as a starting point in their analysis.
ReShape Lifesciences March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ReShape Lifesciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ReShape Lifesciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of ReShape Lifesciences based on widely used predictive technical indicators. In general, we focus on analyzing ReShape Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ReShape Lifesciences's daily price indicators and compare them against related drivers.
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.